Latest From Orthox Ltd.
Global sales of orthobiologics for musculoskeletal soft tissue replacement and regeneration are predicted to hit $1.4bn by 2021, driven largely by rising numbers of sports injuries requiring treatment, but also by a higher prevalence of osteoarthritis and a need for innovative treatments for musculoskeletal repair. This article offers an in-depth look at the orthobiologics market landscape for cartilage, meniscus and ligament/tendon replacement and regeneration, as well as insight from an orthopedic surgeon. It also analyzes key players in these markets and highlights emerging trends and the greatest barriers for wider adoption of products.
Although the U.S. market for sports medicine products is dominated by conservative care products, new surgical techniques and products, including arthroscopy products and surgical implants, are fueling growth in the market, which is projected to reach almost $15.5 billion by 2018.
Although the US sports medicine market is dominated by conservative care treatments, new surgical techniques, arthroscopy products and surgical implants are fueling growth in the market, which is projected to reach almost $15.5 billion by 2018. Industry consolidation and dealmaking among orthopedic manufacturers has yielded several partnerships and M&As that have included a sports medicine element.
- Implantable Devices
- Therapeutic Areas
- Musculoskeletal & Connective Tissue Disorders
- Western Europe
- Parent & Subsidiaries
- Orthox Ltd.
- Senior Management
- Nick Skaer, CEO
- Contact Info
Phone: (0) 1235 232 111
184 Milton Park
Abingdon, OX14 4SE
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.